#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Encephalitis autoimmune Polycystic liver disease Pneumonia Thrombocytosis Congenital disorder of glycosylation Noonan syndrome Necrotising myositis Systemic lupus erythematosus Breast angiosarcoma metastatic Non-Hodgkin's lymphoma unspecified histology indolent Renal cell carcinoma Glomerulonephritis membranoproliferative Stevens-Johnson syndrome Chronic graft versus host disease in skin Neoplasm More trials…

    Learn about Rare Diseases

    Nephroblastoma – Basic Information Bronchiolitis obliterans syndrome Chondrosarcoma – Trials in Disease Alveolar rhabdomyosarcoma – Diagnostics Sarcoma – Treatment Urea cycle disorder – Diagnostics Mucopolysaccharidosis III – Treatment Vascular malformation – Treatment Atypical teratoid/rhabdoid tumour of CNS – Trials in Disease Primary immunodeficiency syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Quavonlimab Sodium Tralokinumab Haloperidol MARALIXIBAT ZIRCONIUM (89ZR) GIRENTUXIMAB Dersimelagon Phosphate Pasireotide Diaspartate Rct2100 SODIUM IBANDRONATE Benralizumab LUNRESERTIB Pemetrexed Disodium Levocabastine Hydrochloride Ttx-030 Galcanezumab Tusamitamab Ravtansine Amikacin Metoprolol Tartrate Camphor More therapies…

    Learn about Your Condition

    Mixed-type liposarcoma Rhabdomyosarcoma Carotid artery stenosis Myeloproliferative neoplasm Acute respiratory failure Exposure via breast milk Cardiac valve disease Pulmonary congestion Androgenetic alopecia Interstitial lung disease Post procedural swelling Cervix carcinoma stage III Rectal neoplasm Thymoma malignant Gastrointestinal disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bipolar I disorder

  • A study to evaluate the safety and effectiveness of azetukalner in patients with bipolar depression

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azetukalner
    Bulgaria France Germany Spain

  • A study to evaluate the effectiveness and safety of azetukalner in patients experiencing depressive episodes associated with bipolar disorder.

    Recruiting

    3 1
    Investigated Diseases:
    • Bipolar I disorder
    Investigated Drugs:
    • Azetukalner
    Bulgaria Germany Poland Spain

  • A study testing xanomeline tartrate and trospium chloride added to current treatment for adults with bipolar I disorder experiencing mania

    Recruiting

    3 1
    Investigated Diseases:
    • Bipolar I disorder
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Denmark France Italy Poland Romania

  • Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

    Recruiting

    3 1 1
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Croatia Denmark France Hungary Italy +5

  • Study of trospium chloride and xanomeline tartrate (KarXT) for treating manic episodes in adults with bipolar I disorder

    Recruiting

    3 1
    Investigated Diseases:
    • Bipolar I disorder
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Croatia Romania Slovakia Spain Sweden

  • Study of trospium chloride and xanomeline tartrate (KarXT) for treatment of manic episodes in adults with bipolar I disorder

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bipolar I disorder
    Investigated Drugs:
    • Trospium Chloride
    • Xanomeline Tartrate
    Bulgaria Hungary Poland
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!